Education
About Us
Working with TipRanks
Follow Us
Transgene SA (FR:TNG)
:TNG
TNG Stock Chart & Stats
€0.94
<€0.01(0.40%)
At close: 4:00 PM EST
€0.94
<€0.01(0.40%)
Day’s Range― - ―
52-Week Range€0.53 - €1.50
Previous CloseN/A
Volume15.92K
Average Volume (3M)129.86K
Market Cap
€232.82M
Enterprise Value€126.05M
Total Cash (Recent Filing)€16.77M
Total Debt (Recent Filing)€30.57M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Mar 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding274,186,700
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)5.22
Price to Sales (P/S)12.49
P/FCF Ratio-2.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase I Results For TG4050The positive Phase I results for TG4050 demonstrate the potential efficacy of Transgene's immunotherapy approach, supporting long-term growth prospects in the oncology market.
Financial Stability Until 2026Securing financial stability until 2026 provides Transgene with the runway to advance its R&D initiatives without immediate capital constraints, enhancing its strategic execution.
Strategic Focus On Myvac PlatformFocusing on the myvac platform aligns Transgene's resources with high-value opportunities, potentially capturing significant market share in personalized cancer vaccines.
Bears Say
Significant Revenue DeclineThe drastic revenue decline highlights challenges in monetizing its pipeline, which could impact long-term financial sustainability and operational funding.
Negative Cash FlowPersistent negative cash flow indicates ongoing liquidity issues, which may constrain the company's ability to invest in growth and R&D without additional funding.
Uncertainty In Regulatory Pathway For TG4050Regulatory uncertainty for TG4050 could delay commercialization, affecting revenue timelines and increasing the risk associated with the product's development.
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.53 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €232.82M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Mar 24, 2026 which is in 36 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 274,186,700 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Technical Analysis
Genfit
―
Innate Pharma SA
―
DBV Technologies
―
Nanobiotix
―
OSE Immunotherapeutics SA
―